Related Experiment Videos
Rheumatoid arthritis: more aggressive approach improves outlook
1Brigham and Women's Hospital, Rheumatology-Immunology-Allergy, Arthritis Center, Harvard Medical School, Boston, Mass 02115, USA.
Cleveland Clinic Journal of Medicine
|June 16, 2004
Summary
Early intervention with disease-modifying antirheumatic drugs (DMARDs) like methotrexate is now standard for rheumatoid arthritis, aiming to slow progression and prevent joint damage. Biologic agents targeting tumor necrosis factor-alpha are also used.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Historically, rheumatoid arthritis treatment focused on symptom management after joint damage occurred.
- Current treatment paradigms have shifted towards early intervention to prevent disease progression.
Purpose of the Study:
- To highlight the evolution of rheumatoid arthritis treatment strategies.
- To emphasize the importance of early initiation of disease-modifying antirheumatic drugs (DMARDs).
Main Methods:
- Review of historical and current treatment protocols for rheumatoid arthritis.
- Discussion of the role of methotrexate and biologic response modifiers.
Main Results:
- Early use of DMARDs like methotrexate is now preferred over NSAIDs and corticosteroids alone.
- Biologic agents, such as those targeting tumor necrosis factor-alpha, offer alternative or adjunctive therapies.
Conclusions:
- Modern rheumatoid arthritis management prioritizes early DMARDs to retard disease progression and prevent joint erosion.
- Advanced therapies, including biologics, provide options for managing inflammation and disease activity.